Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher

Researchers

Matthias Holdhoff, M.D., Ph.D.

Photo of Dr. Matthias Holdhoff, M.D., Ph.D.
  • Associate Professor of Oncology
Male

Languages: English, German

Expertise

Brain Cancer, Brain Tumors, Medical Oncology, Neuro-Oncology, Primary central nervous system (CNS) lymphoma

Research Interests

Clinical Trials in Primary Brain Cancers; Translational Research in Neuro-Oncology

Request an Appointment

Insurance Information

Maryland

410-955-8964

Outside of Maryland

410-464-6641
Request Appointment

International Patients

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8964

Background

Dr. Matthias Holdhoff is a medical oncologist in the Brain Cancer Program at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, as well as associate professor of oncology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is on primary brain cancers and central nervous system lymphomas. He practices at The Sidney Kimmel Comprehensive at Johns Hopkins Hospital in Baltimore. He is board-certified in internal medicine and medical oncology.  

Dr. Holdhoff earned his medical degree from Freie Universität Berlin and received his doctorate degree at Charité University Medicine Berlin. He completed a residency in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training within the Ludwig Center for Cancer Genetics and Therapeutics (Vogelstein lab).

Dr. Holdhoff is a clinical translational investigator in neuro-oncology. His research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations.  

Dr. Holdhoff is panel member for the National Comprehensive Cancer Network’s guidelines for cancers of the central nervous system. He was recipient of an ASCO Young Investigator Award and Merit Award and he was awarded the Director’s Teaching Award in Clinical Sciences at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He serves as the Director of the Solid Tumor Inpatient Service at the Sidney Kimmel Comprehensive Cancer Center, and he is a faculty member on the Janeway firm of the Osler Internal Medicine Residency Program at Johns Hopkins Hospital.

...read more

Titles

  • Associate Professor of Oncology
  • Associate Professor of Neurosurgery
  • Joint Appointment in Medicine

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD, Freie Universitat Berlin (2003)

Residencies

  • Johns Hopkins Bayview Medical Center / Internal Medicine (2007)

Fellowships

  • Johns Hopkins University School of Medicine / Oncology (2010)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2007)
  • American Board of Internal Medicine / Oncology (2009)

Research & Publications

Research Summary

Dr. Holdhoff's research is focused on translational research projects and clinical trials in neuro-oncology. His clinical research is concentrated on early phase therapeutic clinical trials in malignant gliomas, including glioblastomas, as well as in primary central nervous system lymphomas. He is leading or participating in multiple brain cancer trials, including within the Adult Brain Tumor Consortium. In addition, he is working on novel biomarkers to assess response and disease activity, including liquid biopsy approaches, in malignant gliomas and primary central nervous system lymphomas.

Selected Publications

View all on Pubmed

Holdhoff M, Ye X, Piotrowski AF, Strowd RE, Seopaul S, Lu Y, Barker NJ, Sivakumar A, Rodriguez FJ, Grossman SA, Burger PC. The consistency of neuropathological diagnoses in patients undergoing surgery for suspected recurrence of glioblastoma. J Neurooncol. 2019 Jan;141(2):347-354. doi: 10.1007/s11060-018-03037-3. Epub 2018 Nov 9. PMID: 30414096; PMCID: PMC6342857.

Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol. 2019

Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro Oncol. 2017 Jun 1;19(6):845-852. doi: 10.1093/neuonc/nox020. PMID: 28371832; PMCID: PMC5464434.

Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R. Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization. Clin Cancer Res. 2017 Jun 15;23(12):3150-3157. doi: 10.1158/1078-0432.CCR-16-1490. Epub 2016 Dec 29. PMID: 28034905; PMCID: PMC5474132.

Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014 Jul 15;83(3):235-9. PMID:24928128

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button